BioXcel Therapeutics (BTAI) EPS (Weighted Average and Diluted) (2022 - 2025)
Historic EPS (Weighted Average and Diluted) for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to -$2.18.
- BioXcel Therapeutics' EPS (Weighted Average and Diluted) rose 5766.99% to -$2.18 in Q3 2025 from the same period last year, while for Sep 2025 it was -$9.04, marking a year-over-year increase of 9215.75%. This contributed to the annual value of -$31.47 for FY2024, which is 6799.73% up from last year.
- According to the latest figures from Q3 2025, BioXcel Therapeutics' EPS (Weighted Average and Diluted) is -$2.18, which was up 5766.99% from -$2.45 recorded in Q2 2025.
- Over the past 5 years, BioXcel Therapeutics' EPS (Weighted Average and Diluted) peaked at -$1.12 during Q1 2022, and registered a low of -$92.93 during Q4 2023.
- Its 4-year average for EPS (Weighted Average and Diluted) is -$9.22, with a median of -$1.96 in 2022.
- Per our database at Business Quant, BioXcel Therapeutics' EPS (Weighted Average and Diluted) crashed by 464132.65% in 2023 and then surged by 9399.05% in 2024.
- Quarter analysis of 4 years shows BioXcel Therapeutics' EPS (Weighted Average and Diluted) stood at -$1.96 in 2022, then plummeted by 4641.33% to -$92.93 in 2023, then soared by 93.99% to -$5.58 in 2024, then soared by 60.96% to -$2.18 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$2.18 for Q3 2025, versus -$2.45 for Q2 2025 and -$1.5 for Q1 2025.